Protection to respiratory challenge of Brucella abortus strain 2308 in the lung

Vaccine

Volumn 31, Issue 38, 2013, Pages 4103-4110

  Surendran, Naveen ^a,c   Sriranganathan, Nammalwar ^a   Boyle, Stephen M ^a   Hiltbold, Elizabeth M ^b   Tenpenny, Nancy ^a   Walker, Michelle ^a   Zimmerman, Kurt ^a   Werre, Stephen ^a   Witonsky, Sharon G ^a  

^a CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Brucella; Dendritic cell; Respiratory

Indexed keywords

BRUCELLA ABORTUS RB51 TOLL LIKE RECEPTOR 2 VACCINE; BRUCELLA ABORTUS RB51 TOLL LIKE RECEPTOR 4 VACCINE; BRUCELLA ABORTUS RB51 TOLL LIKE RECEPTOR 9 VACCINE; BRUCELLA ABORTUS RB51 VACCINE; BRUCELLA ABORTUS RB51 WBOA VACCINE; BRUCELLA VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL GENE; BACTERIAL STRAIN; BRUCELLA ABORTUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VACCINATION; WBOA GENE;

BRUCELLA; DENDRITIC CELL; RESPIRATORY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, CD8; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; DENDRITIC CELLS; FEMALE; INTEGRIN ALPHA CHAINS; INTERLEUKIN-17; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; SPLEEN; TH1 CELLS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9;

EID: 84881545767     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.078     Document Type: Article

References (36)

1. Acha P., Szyfres B. Zoonoses and communicable diseases common to man and animal 2001, Pan American Health Organization/World Health Organization.
2. Corbel M.J. Brucellosis in humans and animals 2006, World Health Organisation.
3. Nene V., Kole C. Genome mapping and genomics in animal-associated microbes 2009, Springer-Verlag, Berlin/Heidelberg. 1st ed.
4. Pappas G., Panagopoulou P., Christou L., Akritidis N. Brucella as a biological weapon. Cell Mol Life Sci 2006, 63:2229-2236.
5. Surendran N., Sriranganathan N., Lawler H., Boyle S.M., Hiltbold E.M., Heid B., et al. Efficacy of vaccination strategies against intranasal challenge with Brucella abortus in BALB/c mice. Vaccine 2011, 29:2749-2755.
6. Schurig G.G., Roop R.M., Bagchi T., Boyle S., Buhrman D., Sriranganathan N. Biological properties of RB51: a stable rough strain of Brucella abortus. Vet Microbiol 1991, 28:171-188.
7. Surendran N., Hiltbold E.M., Heid B., Sriranganathan N., Boyle S.M., Zimmerman K.L., et al. Live Brucella abortus rough vaccine strain RB51 stimulates enhanced innate immune response in vitro compared to rough vaccine strain RB51SOD and virulent smooth strain 2308 in murine bone marrow-derived dendritic cells. Vet Microbiol 2011, 147:75-82.
8. Surendran N., Hiltbold E.M., Heid B., Sriranganathan N., Boyle S.M., Zimmerman K.L., et al. Heat-killed and gamma-irradiated Brucella strain RB51 stimulates enhanced dendritic cell activation, but not function compared with the virulent smooth strain 2308. FEMS Immunol Med Microbiol 2010, 60:147-155.
9. Ficht T.A., Kahl-McDonagh M.M., Arenas-Gamboa A.M., Rice-Ficht A.C. Brucellosis: the case for live, attenuated vaccines. Vaccine 2009, 27(Suppl. 4):D40-D43.
10. Kahl-McDonagh M.M., Arenas-Gamboa A.M., Ficht T.A. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infect Immun 2007, 75:4923-4932.
11. Vemulapalli R., He Y., Cravero S., Sriranganathan N., Boyle S.M., Schurig G.G. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect Immun 2000, 68:3286-3289.
12. Surendran N., Hiltbold E.M., Heid B., Akira S., Standiford T.J., Sriranganathan N., et al. Role of TLRs in Brucella mediated murine DC activation in vitro and clearance of pulmonary infection in vivo. Vaccine 2012.
13. Vemulapalli R., He Y., Buccolo L.S., Boyle S.M., Sriranganathan N., Schurig G.G. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. Infect Immun 2000, 68:3927-3932.
14. Rajasekaran P., Surendran N., Seleem M.N., Sriranganathan N., Schurig G.G., Boyle S.M. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge. Vaccine 2011, 29:3106-3110.
15. Billard E., Dornand J., Gross A. Interaction of Brucella suis and Brucella abortus rough strains with human dendritic cells. Infect Immun 2007, 75:5916-5923.
16. Billard E., Dornand J., Gross A. Brucella suis prevents human dendritic cell maturation and antigen presentation through regulation of tumor necrosis factor alpha secretion. Infect Immun 2007, 75:4980-4989.
17. Bhan U., Lukacs N.W., Osterholzer J.J., Newstead M.W., Zeng X., Moore T.A., et al. TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. J Immunol 2007, 179:3937-3946.
18. Desch A.N., Randolph G.J., Murphy K., Gautier E.L., Kedl R.M., Lahoud M.H., et al. CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med 2011, 208:1789-1797.
19. Furuhashi K., Suda T., Hasegawa H., Suzuki Y., Hashimoto D., Enomoto N., et al. Mouse Lung CD103+ and CD11bhigh dendritic cells preferentially induce distinct CD4+ T cell responses. Am J Resp Cell Mol Biol 2011.
20. Lombardi V., Van Overtvelt L., Horiot S., Moussu H., Chabre H., Louise A., et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 2008, 38:1819-1829.
21. Fernandes D.M., Jiang X., Jung J.H., Baldwin C.L. Comparison of T cell cytokines in resistant and susceptible mice infected with virulent Brucella abortus strain 2308. FEMS Immunol Med Microbiol 1996, 16:193-203.
22. Fu C.L., Chuang Y.H., Huang H.Y., Chiang B.L. Induction of IL-10 producing CD4+ T cells with regulatory activities by stimulation with IL-10 gene-modified bone marrow derived dendritic cells. Clin Exp Immunol 2008, 153:258-268.
23. Helft J., Manicassamy B., Guermonprez P., Hashimoto D., Silvin A., Agudo J., et al. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J Clin Investig 2012, 122:4037-4047.
24. Leepiyasakulchai C., Ignatowicz L., Pawlowski A., Kallenius G., Skold M. Failure to recruit anti-inflammatory CD103+ dendritic cells and a diminished CD4+ Foxp3+ regulatory T cell pool in mice that display excessive lung inflammation and increased susceptibility to Mycobacterium tuberculosis. Infect Immun 2012, 80:1128-1139.
25. Olson M., Russ B., Doherty P., Turner S., Influenza S.J. A virus-specific CD8 T-cell responses: from induction to function. Future Virol 2010, 5:175-183.
26. Clapp B., Skyberg J.A., Yang X., Thornburg T., Walters N., Pascual D.W. Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses. Infect Immun 2011, 79:4165-4174.
27. Pasquali P., Rosanna A., Pistoia C., Petrucci P., Ciuchini F. Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. Infect Immun 2003, 71:2326-2330.
28. Vemulapalli R., He Y., Sriranganathan N., Boyle S.M., Schurig G.G. Brucella abortus RB51: enhancing vaccine efficacy and developing multivalent vaccines. Vet Microbiol 2002, 90:521-532.
29. Fernandes D.M., Baldwin C.L. Interleukin-10 downregulates protective immunity to Brucella abortus. Infect Immun 1995, 63:1130-1133.
30. Pasquali P., Adone R., Gasbarre L.C., Pistoia C., Ciuchini F. Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection. Infect Immun 2001, 69:6541-6544.
31. Pasquali P., Thornton A.M., Vendetti S., Pistoia C., Petrucci P., Tarantino M., et al. CD4+CD25+T regulatory cells limit effector T cells and favor the progression of brucellosis in BALB/c mice. Microbes Infect/Institut Pasteur 2010, 12:3-10.
32. Fernandes H., Barchuk W., Fernandes G., Ramachandra S., Chou C., Raveche E. Regulation of cll by interleukin-10 - role of antisense IL-10. Oncol Rep 1995, 2:985-989.
33. Pasquevich K.A., Ibanez A.E., Coria L.M., Garcia Samartino C., Estein S.M., Zwerdling A., et al. An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice. PLoS ONE 2011, 6:e16203.
34. Janssen W.J., Barthel L., Muldrow A., Oberley-Deegan R.E., Kearns M.T., Jakubzick C., et al. Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury. Am J Resp Crit Care Med 2011, 184:547-560.
35. Edelson B.T., Bradstreet T.R., Hildner K., Carrero J.A., Frederick K.E., Kc W., et al. CD8alpha(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity 2011, 35:236-248.
36. Gao X., Wang S., Fan Y., Bai H., Yang J., Yang X. CD8+ DC, but Not CD8(-)DC, isolated from BCG-infected mice reduces pathological reactions induced by mycobacterial challenge infection. PLoS ONE 2010, 5:e9281.